Prognostic Impact of TP53 Mutations in Metastatic Nonsquamous Non–small-cell Lung Cancer

Laurent Mathiot; Benoit Nigen; Thomas Goronflot; Sandrine Hiret; Ludovic Doucet; Elvire Pons-Tostivint; Jaafar Bennouna; Marc G. Denis; Guillaume Herbreteau; Judith Raimbourg

doi:10.1016/j.cllc.2023.12.004

journal article Open Access May 01, 2024

Prognostic Impact of TP53 Mutations in Metastatic Nonsquamous Non–small-cell Lung Cancer

Benoit Nigen Thomas Goronflot Sandrine Hiret Ludovic Doucet Elvire Pons-Tostivint Jaafar Bennouna Marc G. Denis Guillaume Herbreteau Judith Raimbourg

Clinical Lung Cancer Vol. 25 No. 3 pp. 244-253.e2 · Elsevier BV

View at Publisher Save 10.1016/j.cllc.2023.12.004

Topics

No keywords indexed for this article. Browse by subject →

References

37

[1]

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

Martin Reck, Delvys Rodríguez-Abreu, Andrew G. Robinson et al.

New England Journal of Medicine 2016 10.1056/nejmoa1606774

[2]

Gandhi "Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer" N Engl J Med (2018) 10.1056/nejmoa1801005

[3]

Planchard "Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up" Ann Oncol (2018) 10.1093/annonc/mdy275

[4]

Doroshow "Immunotherapy in non–small cell lung cancer: facts and hopes" Clin Cancer Res (2019) 10.1158/1078-0432.ccr-18-1538

[5]

Cyriac "Emerging biomarkers for immune checkpoint inhibition in lung cancer" Semin Cancer Biol (2018) 10.1016/j.semcancer.2018.05.006

[6]

Collisson "Comprehensive molecular profiling of lung adenocarcinoma" Nature (2014) 10.1038/nature13385

[7]

Leroy "Recommended guidelines for validation, quality control, and reporting of TP53 variants in clinical practice" Cancer Res (2017) 10.1158/0008-5472.can-16-2179

[8]

Fischer "Census and evaluation of p53 target genes" Oncogene (2017) 10.1038/onc.2016.502

[9]

Vousden "Blinded by the light: the growing complexity of p53" Cell (2009) 10.1016/j.cell.2009.04.037

[10]

Marei "p53 signaling in cancer progression and therapy" Cancer Cell Int (2021) 10.1186/s12935-021-02396-8

[11]

Rabik "Molecular mechanisms of resistance and toxicity associated with platinating agents" Cancer Treat Rev (2007) 10.1016/j.ctrv.2006.09.006

[12]

Gregorc "Relevance of p53, bcl-2 and Rb expression on resistance to cisplatin-based chemotherapy in advanced non-small cell lung cancer" Lung Cancer (2003) 10.1016/s0169-5002(02)00391-4

[13]

Harada "Predictive value of expression of P53, Bcl-2 and lung resistance-related protein for response to chemotherapy in non-small cell lung cancers" Cancer Sci (2003) 10.1111/j.1349-7006.2003.tb01453.x

[14]

Lin "Meta-analysis of P53 expression and sensitivity to platinum-based chemotherapy in patients with non-small cell lung cancer" Medicine (Baltimore) (2021) 10.1097/md.0000000000024194

[15]

Fu "A special prognostic indicator: tumor mutation burden combined with immune infiltrates in lung adenocarcinoma with TP53 mutation" Transl Cancer Res (2021) 10.21037/tcr-21-565

[16]

Lin "Prognostic biomarker TP53 mutations for immune checkpoint blockade therapy and its association with tumor microenvironment of lung adenocarcinoma" Front Mol Biosci [Internet] (2020)

[17]

Assoun "Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer" Lung Cancer Amst Neth (2019) 10.1016/j.lungcan.2019.04.005

[18]

Olivares-Hernández "Immunohistochemical Assessment of the P53 Protein as a Predictor of Non-Small Cell Lung Cancer Response to Immunotherapy" Front Biosci Landmark Ed (2022) 10.31083/j.fbl2703088

[19]

de Andrade "The TP53 database: transition from the International Agency for Research on Cancer to the US National Cancer Institute" Cell Death Differ (2022) 10.1038/s41418-022-00976-3

[20]

Team (2012)

[21]

Real-world outcomes of immunotherapy–based regimens in first-line advanced non-small cell lung cancer

David Waterhouse, Jenny Lam, Keith A. Betts et al.

Lung Cancer 2021 10.1016/j.lungcan.2021.04.007

[22]

Hainaut "Patterns of p53 G→T transversions in lung cancers reflect the primary mutagenic signature of DNA-damage by tobacco smoke" Carcinogenesis (2001) 10.1093/carcin/22.3.367

[23]

Le Calvez "TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke: distinct patterns in never, former, and current smokers" Cancer Res (2005) 10.1158/0008-5472.can-05-0551

[24]

Zhao "Impact of smoking history on response to immunotherapy in non-small-cell lung cancer: a systematic review and meta-analysis" Front Oncol (2021)

[25]

Popat "Association between smoking history and overall survival in patients receiving pembrolizumab for first-line treatment of advanced non-small cell lung cancer" JAMA Netw Open (2022) 10.1001/jamanetworkopen.2022.14046

[26]

Cortez "PDL1 Regulation by p53 via miR-34" JNCI J Natl Cancer Inst (2016) 10.1093/jnci/djv303

[27]

Huang "Clinicopathologic and genomic landscape of non-small cell lung cancer brain metastases" Oncologist (2022) 10.1093/oncolo/oyac094

[28]

Leroy "TP53 mutations in human cancer: database reassessment and prospects for the next decade" Hum Mutat (2014) 10.1002/humu.22552

[29]

Vaughan "Gain-of-function p53 activates multiple signaling pathways to induce oncogenicity in lung cancer cells" Mol Oncol (2017) 10.1002/1878-0261.12068

[30]

Barta "The lung-enriched p53 mutants V157F and R158L/P regulate a gain of function transcriptome in lung cancer" Carcinogenesis (2020) 10.1093/carcin/bgz087

[31]

Sun "Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma" EBioMedicine (2020) 10.1016/j.ebiom.2020.102990

[32]

Zhao "TP53 somatic mutations are associated with poor survival in non-small cell lung cancer patients who undergo immunotherapy" Aging (2020) 10.18632/aging.103502

[33]

Pan "TP53 gain-of-function and non–gain-of-function mutations are differentially associated with sidedness-dependent prognosis in metastatic colorectal cancer" J Clin Oncol (2022) 10.1200/jco.21.02014

[34]

Ben-Cohen "TP53_PROF: a machine learning model to predict impact of missense mutations in TP53" Brief Bioinform (2022) 10.1093/bib/bbab524

[35]

Tomasini "Effect of coexisting KRAS and TP53 mutations in patients treated with chemotherapy for non-small-cell lung cancer" Clin Lung Cancer (2019) 10.1016/j.cllc.2018.12.009

[36]

Shepherd "Pooled analysis of the prognostic and predictive effects of TP53 comutation status combined with KRAS or EGFR mutation in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy" J Clin Oncol (2017) 10.1200/jco.2016.71.2893

[37]

Wang "The role of distinct co-mutation patterns with TP53 mutation in immunotherapy for NSCLC" Genes Dis (2022) 10.1016/j.gendis.2020.04.001

Cited By

14

p53: An Immune Ecosystem Manipulator

Zhigang Nian, Yingchao Dou · 2025

Clinical Cancer Research

Metrics

14

Citations

37

References

Details

Published: May 01, 2024
Vol/Issue: 25(3)
Pages: 244-253.e2
License: View

Authors

Elvire Pons-Tostivint

Cite This Article

Laurent Mathiot, Benoit Nigen, Thomas Goronflot, et al. (2024). Prognostic Impact of TP53 Mutations in Metastatic Nonsquamous Non–small-cell Lung Cancer. Clinical Lung Cancer, 25(3), 244-253.e2. https://doi.org/10.1016/j.cllc.2023.12.004

Prognostic Impact of TP53 Mutations in Metastatic Nonsquamous Non–small-cell Lung Cancer

You May Also Like